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Objectives
Atopic dermatitis (AD), a relapsing skin disorder characterized by severe itching and impair- ment of quality of 
life, affects 10–20% of children and 3-5% of adults worldwide. Vernonia amygdalina (VAM) is a plant which leaf 
extracts have antioxidant, antitumor activities in experimental studies. We previously demonstrated that VAM 
extracts display anti-inflammatory effects in animal model of atopic dermatitis. The present study aimed to 
analyze the main chemical compounds from the leaf extracts and their anti-allergic effects in patients with AD 
and allergic contact dermatitis (ACD). 
Methods
HPLC analysis of the aqueous (VAM1) and alcoholic (VAM2) extracts was performed in order to identify their 
main components. Gas chromatography mass spectrometry (GC-MS) showed lipid contents of each extract. A 
clinical trial was conducted that included 63 students suffering from mild to moderate AD or ACD. They were 
randomly assigned one of the following treatments: VAM1, VAM2, dexamethasone (steroid) or vaseline. The 
severity of the disease was evaluated using the “eczema area severity index” (EASI) scoring system. The 
evaluation of skin symptoms and signs was performed once a week for a total of four weeks. Hematological, 
immunological assays and markers of hepatic function (ALT, ASAT) assays were performed in representative 
patients. Signed informed consent were obtained from patients’ parents. 
Results 
HPLC analysis showed that VAM1 mainly contains polyphenols (flavonoids), alkaloids and saponins; while 
VAM2 comprised terpenes and carotenoids. In addition, GC-MS analysis revealed that this species of VAM has 
different chemical composition as compared with the plant from the western and southern regions of Africa. 
VAM 1 mainly contains various inositols (87%); however, for VAM2, aliphatic acids such (as hexadecanoic acid, 
octadecanoic acid) represent 61%. Regarding anti-inflammatory compounds, the most active isolated terpene 
from the plant is vernodalin and, on the other side, the most active flavonoid is dicaffeoyl- quinic acid. Regarding 
the clinical trial, dexamethasone, VAM1 and VAM2 displayed a good anti-itch effect as compared with Vaseline 
(p<0.001, t test). In addition, the anti-itch effect of VAM2 was greater than that of dexamethasone (p<0.05). A 
marked improvement of EASI score was observed in dexamethasone, VAM1 and VAM2-treated patients (vs. 
Vaseline; p<0.001 by t test), with dexamethasone having a slightly higher proportion of patients clinically cured 
within five weeks of treatment (82%), followed by VAM2 (79%) and VAM1 (76%). 
Conclusion
This is the very first conducted clinical study on VAM, which displayed an anti-allergic activity similar to that of 
dexamethasone; this suggests that VAM may possibly serve as alternative therapeutic agent for atopic/eczema 
dermatitis syndrome. Detailed results will be discussed during the research meeting. 
